Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-14
SponsorMinistry of Health, Saudi Arabia

About this trial

We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn.

Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.

Eligibility criteria

Qualifiers

positive DAT and blood group iso-immunization (ABO / RH incompatibility);and /or

HGB decline by 2g/dl within 24hour.

Disqualifiers

Major congenital abnormalities,

Surgical problems,

Direct hyperbilirubinemia

Sepsis

Trial design

Treatments tested in this trial

  • phototherapy

Treatment groups

84 Participants
are divided into 2 treatment groups